

# Supplemental Table - United States Cutaneous Lymphoma Consortium Recommendations for Treatment of Cutaneous Lymphomas During the COVID-19 Pandemic

| Disease Category  | Imiquimod | Topical retinoids | Mechlorethamine gel or ointment | Topical steroids | Intralesional steroids | Excision | Localized EBRT* | NBUVB phototx** | ECP <sup>‡</sup> | Oral retinoids*** | PUVA phototx | Prednisone < 20mg/d**** | MTX****   | Total skin EBRT | IFN sc injection^ | Vorinostat capsules | Brentuximab vedotin IV | Mogamulizumab IV | Romidepsin IV | Pralatrexate IV | Gemcitabine^^ | Rituximab IV | CHOP IV | Alemtuzumab sc injection | Allogeneic hematopoietic cell transplant^^^ | Disease Name   |                              |
|-------------------|-----------|-------------------|---------------------------------|------------------|------------------------|----------|-----------------|-----------------|------------------|-------------------|--------------|-------------------------|-----------|-----------------|-------------------|---------------------|------------------------|------------------|---------------|-----------------|---------------|--------------|---------|--------------------------|---|--|------------------------------|
|                   |           |                   |                                 |                  |                        |          |                 |                 |                  |                   |              |                         |           |                 |                   |                     |                        |                  |               |                 |               |              |         |                          |   |  | Least Concern                |
| HIGH RISK         | NR        | NR                | PBT                             | NC               | NR                     | NR       | NC              | NR              | PP or II         | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | DC                       | PP  | Sézary syndrome  |                              |
|                   | NR        | NR                | NR                              | NC               | NR                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | Extranodal Natural Killer/T-cell lymphoma                      |                              |
|                   | NR        | NR                | NR                              | NC               | NR                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NR                | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | Primary cutaneous gamma-delta TCL                              |                              |
|                   | NR        | NR                | NR                              | NC               | NR                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NR                | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | CD8+ aggressive epidermotropic cytotoxic TCL                   |                              |
|                   | NR        | NR                | PBT                             | NC               | NR                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | MF Stage IV (blood, lymph node, visceral involvement)          |                              |
|                   | PBT       | NR                | PBT                             | NC               | PP                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | MF Stage IIB (multiple tumors)                                 |                              |
|                   | NR        | NR                | NR                              | NC               | PP                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | NR        | PP              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | PP  | Primary cutaneous diffuse large B-cell lymphoma, leg type      |                              |
|                   | NC        | NR                | PBT                             | NC               | PP                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | CA or II         | CA or II      | CA or II        | CA or II      | NR           | NR      | NR                       | PP  | Folliculotropic MF (thick plaque/tumor)                        |                              |
|                   | NR        | NR                | PBT                             | NC               | NR                     | NR       | NC              | NR              | NR               | PP or II          | NC or PBT    | NR                      | DD or PBT | DD or II        | PP                | NC or PBT           | DD or DC               | II               | CA or II      | CA or II        | CA or II      | CA or II     | NR      | NR                       | NR  | PP   | MF Stage III (erythrodermic) |
|                   | NC        | NR                | PBT                             | NC               | PP                     | NR       | NC              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | NR               | NR            | CA or II        | NR            | NR           | NR      | NR                       | NR  | MF Stage IIB (few tumors)                                      |                              |
| INTERMEDIATE RISK | NR        | NR                | NR                              | NC               | NR                     | NR       | PP              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Primary cutaneous diffuse large B-cell lymphoma (not leg type) |                              |
|                   | NR        | NR                | NR                              | NC               | NR                     | NR       | PP              | NR              | NR               | NC or PBT         | NR           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | NR               | CA or II      | NR              | NR            | NR           | NR      | NR                       | NR  | Subcutaneous panniculitis-like TCL                             |                              |
|                   | NC        | NC                | NC                              | NC               | PP                     | NR       | PP              | PP              | PP               | NC or PBT         | PP           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | NR               | CA or II      | NR              | NR            | NR           | NR      | NR                       | NR  | MF stage IB (plaque), IIA (reactive lymph nodes)               |                              |
|                   | NC        | NC                | NC                              | NC               | PP                     | NR       | PP              | PP              | PP               | NC or PBT         | PP           | DD or PBT               | DD or II  | PP              | NC or PBT         | DD or DC            | II                     | NR               | CA or II      | NR              | NR            | NR           | NR      | NR                       | NR  | Folliculotropic MF (follicular papules/patch/thin plaque)      |                              |
|                   | NC        | NC                | NC                              | NC               | PP                     | PP       | NC              | PP              | NR               | NC or PBT         | PP           | DD or PBT               | DD or II  | PP              | NC or PBT         | NR                  | II                     | NR               | CA or II      | NR              | NR            | NR           | NR      | NR                       | NR  | Primary cutaneous anaplastic large cell lymphoma               |                              |
|                   | NR        | NR                | NR                              | NC               | NR                     | NR       | PP              | PP              | PP               | NC or PBT         | PP           | NR                      | NR        | NR              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Granulomatous slack skin & Granulomatous MF                    |                              |
|                   | NC        | NC                | NC                              | NC               | PP                     | NR       | NR              | PP              | NR               | NC or PBT         | PP           | DD or PBT               | DD or II  | PP              | NC or PBT         | NR                  | DC                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Lymphomatoid papulosis   |                              |
|                   | NC        | NC                | NC                              | NC               | NR                     | NR       | NR              | PP              | NR               | NC or PBT         | PP           | NR                      | DD or II  | PP              | NC or PBT         | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | MF stage IA (patch/plaque)                                     |                              |
|                   | NC        | NC                | NC                              | NC               | PP                     | NR       | PP              | PP              | PP               | NC or PBT         | PP           | NR                      | DD or II  | NR              | NC or PBT         | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | NR   | Pagetoid reticulosis         |
|                   | NC        | NC                | NC                              | NC               | PP                     | PP       | PP              | PP              | NR               | NR                | NR           | NR                      | NR        | NR              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | NR   | Acral CD8+ TCL               |
| LOW RISK          | NC        | NC                | NC                              | NC               | PP                     | PP       | PP              | NR              | NR               | NR                | NR           | NR                      | NR        | NR              | NC or PBT         | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | CD4+ pleomorphic small/medium T-cell LPD                       |                              |
|                   | PBT       | PBT               | PBT                             | NC               | PP                     | PP       | PP              | PP              | NR               | NR                | NR           | NR                      | NR        | NR              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Primary cutaneous follicle center B-cell lymphoma              |                              |
|                   | PBT       | PBT               | PBT                             | NC               | PP                     | PP       | PP              | PP              | NR               | NR                | NR           | NR                      | NR        | NR              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Primary cutaneous marginal zone lymphoma                       |                              |
|                   | PBT       | PBT               | PBT                             | NC               | PP                     | PP       | PP              | PP              | NR               | NR                | NR           | NR                      | NR        | NR              | NR                | NR                  | NR                     | NR               | NR            | NR              | NR            | NR           | NR      | NR                       | NR  | Primary cutaneous marginal zone lymphoma                       |                              |

LPD = lymphoproliferative disorder  
MF = mycosis fungoides  
TCL = T-cell lymphoma

CA = Consider alternative therapy during pandemic  
DC = Discontinue during pandemic<sup>AAAA</sup>  
DD = Decrease dose during pandemic  
II = Increase intervals between treatments during pandemic  
NC = No change necessary during pandemic  
NR = Not recommended during pandemic<sup>AAAAA</sup>  
PBT = Possible Bridge Therapy during pandemic  
PP = Postpone therapy to limit travel during pandemic

\* For rapidly growing or ulcerated tumors consider short course  
\*\* Home NBUVB or sun light exposure (heliotherapy) preferred during the pandemic  
\*\*\* Increase intervals for lab testing  
\*\*\*\* May be an important short term bridge therapy to help control symptoms during the pandemic.  
# The benefits of photopheresis should be balanced against the risk of travel during COVID-19 pandemic.  
^ Dose reduction if lymphopenic  
^^ Recommendations may also apply to other single agent chemotherapy.  
^^^ Postpone due to high risk of infectious complications and to limit travel during the pandemic  
AAAA DC applies to patients presently receiving that specific therapy.  
AAAAA NR implies that this therapy should not be started during the pandemic based on benefit/risk ratio. It does not imply that these therapies are recommended after the pandemic.

ECP = extracorporeal photochemotherapy (photopheresis)  
EBRT = electron beam radiotherapy  
IFN = interferon  
IV = intravenous  
MTX = methotrexate  
phototx = phototherapy  
PUVA = psoralen and ultraviolet A  
sc = subcutaneous

HIGH LEVEL THERAPY IMMUNOSUPPRESSION